Advertisement
Advertisement
April 30, 2024
Front Line’s COBRA-OS Device Receives CE Mark Approval
April 30, 2024—Front Line Medical Technologies Inc. recently announced that its Control of Bleeding, Resuscitation, Arterial Occlusion System (COBRA-OS) has been granted CE Mark approval under the new European Medical Device Regulations. It is intended for use in resuscitative endovascular balloon occlusion of the aorta (REBOA) procedures.
The company stated that in addition to its ultra-low profile, the COBRA-OS does not require an over-the-wire technique, which speeds up deployment, allowing more time until definitive care can be provided. It is accompanied by a 4-F mini-access sheath kit and a 10-mL sword-handled syringe.
The 4-F aortic occlusion device is now available to medical providers in the European Union. The COBRA-OS REBOA device was launched in the United States and Canada in February 2022.
Advertisement
Advertisement
